Inspection Record

Catalent Indiana, LLC — FDA 483 Findings

US FDAInspected 2022-09-01Published 2022-10-19 11 findingsOther quality systemEquipment and facilityAseptic processing and sterility assuranceProcess validationComplaint and recall handlingLaboratory and QC controlsDeviation, CAPA, and investigation

Inspectors Logan Williams · Eboni Funderburk · National Expert Muna AlgharibehThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

Records are not maintained so that data therein can be reviewed at least <Redacted B4> to evaluate the quality standards of each drug product to determine the need for changes in specifications or manufacturing or control procedures.

2Equipment and facility

Routine checking of equipment is not performed -according to a written program designed to assure proper performance.

3Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

4Process validation

Your firm failed to establish and follow adequate control procedures to monitor the output and to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.

5Process validation

Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.

6Equipment and facility

Equipment used in the manufacturing of a drug product is not of appropriate design to facilitate operations for its intended use.

7Other quality system

ln-process samples are not representative.

8Complaint and recall handling

Written records of investigation of a drug complaint do not include the findings of the investigation and the follow-up.

9Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, or followed.

10Laboratory and QC controls

Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity.

11Deviation, CAPA, and investigation

Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed.

About this record

Extracted automatically from the document US FDA published on 2022-10-19. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Catalent Indiana, LLC company profile — full history US FDA documents, 2022 Go to Findings search